Dr Jan Van Deursen is a pioneer in cell biology, focusing on senescent cells that stop dividing and accumulate in the body. He directs the Center for Biomedical Discovery’s discovery research efforts into cell ageing. His graduate program matches students with a mentor with similar interests and experience. Jan Van Deursen has helped thousands of scientists, including Dr Childs, understand the causes of ageing.
While a professor, Jan Van Deursen mentored dozens of young scientists. He believed a mentor’s role is crucial, as they give young scientists the initial boost they need to succeed. As a result, young researchers build on the work of their mentors to reach their ultimate potential. His mentorship, as well as his own, helped Dr Childs become an accomplished physician-scientist. However, the research is only part of Jan Van Deursen’s legacy.
Jan Van Deursen’s research has created a biotech company, Unity Biotechnology. His breakthroughs in anti-ageing have attracted big investors, including Jeff Bezos. In addition, he founded a company, Unity Biotechnology, which has attracted big investors, including Jeff Bezos, the richest man in the world. And while he has worked with many people, it has become difficult to gauge whether he’s an ethical person.
Dr Jan Van Deursen’s current research focuses on age-related diseases and cellular senescence, and his work could lead to new therapies for age-related diseases. Currently, he lives in Rochester, Minnesota. His wife and son have been married for 25 years and have three children. In addition, Dr Van Deursen has been married for more than 25 years. So far, Dr Van Deursen’s groundbreaking research has led to many new therapies.
The Netherlands-born van Deursen earned his PhD in cell biology from the University of Nijmegen. He then moved to the US to pursue research opportunities. He developed a stem cell editing program in mice, focusing on regulating gene expression. He also served as director of the transgenic and gene knockout core facility at Mayo Clinic in the United States from 1999 to 2020. By the end of his career, he was named chair of the Biochemistry and Molecular Biology department at Mayo Clinic.
Dr Van Deursen’s research also helped to shed light on the connection between ageing and senescent cells. He has since founded Unity Biotechnology, a publicly traded biopharmaceutical company focusing on removing senescent cells from the body. The company is preparing for clinical trials in osteoarthritis and glaucoma. The University of Texas has reached out to former lab employees to ensure their work is still valued at Mayo Clinic.
Dr Van Deursen applied these technologies to cancer research. In particular, he discovered a protein called BubR1, which ensures faithful chromosome segregation during mitosis. The discovery was causally implicated in various human diseases, including cancer and ageing. He holds a PhD in Cell Biology. He is passionate about advancing science, and his research is recognized as a breakthrough in the field.
After injecting them with his compound, Jan Van Deursen genetically modified two mouse strains to kill senescent cells. Middle-aged mice were injected with the compound twice weekly. Although it did not eliminate the senescent cells, it did kill 50 to 70 percent of them in some tissues. His findings were published in Nature and Science. In 1999, Dr Van Deursen was recruited by Dr Bill Crist and Dr Rick Bram, both from the Mayo Clinic.
